Compare TMDX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | WGS |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 2019 | N/A |
| Metric | TMDX | WGS |
|---|---|---|
| Price | $141.71 | $108.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $144.25 | $138.13 |
| AVG Volume (30 Days) | ★ 660.2K | 554.5K |
| Earning Date | 02-26-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.70 | N/A |
| EPS | ★ 2.54 | 0.07 |
| Revenue | ★ $566,354,000.00 | $402,190,000.00 |
| Revenue This Year | $38.81 | $41.17 |
| Revenue Next Year | $20.49 | $23.53 |
| P/E Ratio | ★ $56.53 | $1,499.76 |
| Revenue Growth | 41.20 | ★ 50.50 |
| 52 Week Low | $55.00 | $55.17 |
| 52 Week High | $156.00 | $170.87 |
| Indicator | TMDX | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 63.09 | 26.62 |
| Support Level | $134.00 | $103.01 |
| Resistance Level | $151.85 | $113.24 |
| Average True Range (ATR) | 6.57 | 8.17 |
| MACD | 1.73 | -2.74 |
| Stochastic Oscillator | 68.91 | 13.21 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.